文献速递神经肿瘤功能神经外科

垂体腺瘤伽玛刀术后垂体功能减退的多中心国际研究

Hypopituitarism after Gamma Knife radiosurgery for pituitary adenomas: a multicenter, international study.
PubMed 文献 · J Neurosurg · 2018-11-09

结果显示248例出现新发垂体激素缺乏,10年垂体功能减退发生率为31.3%,中位发生时间39个月。多因素分析显示较低等剂量线是新发垂体功能减退的独立预测因素。

要点

  • 伽玛刀治疗后垂体功能减退10年累积发生率为31.3%,中位发生时间39个月。
  • 较低等剂量线是新发垂体功能减退的独立预测因素(p=0.001,HR=1.38)。
  • 靶区等剂量线≥50%并避免全鞍区照射可能降低垂体功能减退风险。

核心结论

  • 垂体功能减退仍是垂体腺瘤伽玛刀放射外科治疗最常见的不良效应。
  • 以50%或以上的等剂量线治疗靶区并避免不必要的全鞍区放射外科治疗,可能降低伽玛刀术后垂体功能减退的风险。
  • 需要对这些患者进行随访以发现和治疗潜在的内分泌疾病。

研究设计与样本

  • 排除既往接受过放疗的患者,共1023例符合纳入标准。
  • 治疗病变包括410例无功能垂体腺瘤、262例库欣病和251例肢端肥大症。
  • 中位随访51个月(范围6-246个月)。
  • 采用Cox比例风险模型评估与新发垂体功能减退相关的因素。

主要发现

  • 末次随访时248例出现新发垂体激素缺乏(无功能腺瘤86例、库欣病66例、肢端肥大症96例)。
  • 其中150例(60.5%)为单一激素缺乏,98例(39.5%)为多种激素缺乏。
  • 新发激素缺乏包括皮质醇82例(21.6%)、促甲状腺激素135例(35.6%)、促性腺激素92例(24.3%)、生长激素59例(15.6%)和血管加压素11例(2.9%)。
  • 垂体功能减退的1年、3年、5年、7年和10年累积发生率分别为7.8%、16.2%、22.4%、27.5%和31.3%。
  • 垂体功能减退发生的中位时间为39个月。

关键数值与推荐

  • 单因素分析中,较低等剂量线(p=0.006,HR=8.695)、全鞍区靶向(p=0.033,HR=1.452)以及功能性垂体腺瘤相对于无功能腺瘤(p=0.008,HR=1.510)与新发垂体功能减退发生率增加显著相关。
  • 多因素分析中,仅较低等剂量线是新发垂体功能减退的独立预测因素(p=0.001,HR=1.38)。
  • 推荐以50%或以上的等剂量线治疗靶区,并避免不必要的全鞍区放射外科治疗。

临床怎么用

  • 对垂体腺瘤患者行伽玛刀放射外科治疗时,靶区等剂量线应≥50%,避免不必要的全鞍区照射。
  • 术后需长期随访内分泌功能,以发现和治疗潜在的内分泌疾病。

局限性

  • 本研究为回顾性多中心队列研究,可能存在选择偏倚和信息偏倚。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recurrent or residual adenomas are frequently treated with Gamma Knife radiosurgery (GKRS). The most common complication after GKRS for pituitary adenomas is hypopituitarism. In the current study, the authors detail the timing and types of hypopituitarism in a multicenter, international cohort of pituitary adenoma patients treated with GKRS. METHODS: Seventeen institutions pooled clinical data obtained from pituitary adenoma patients who were treated with GKRS from 1988 to 2016. Patients who had undergone prior radiotherapy were excluded. A total of 1023 patients met the study inclusion criteria. The treated lesions included 410 nonfunctioning pituitary adenomas (NFPAs), 262 cases of Cushing's disease (CD), and 251 cases of acromegaly. The median follow-up was 51 months (range 6-246 months). Statistical analysis was performed using a Cox proportional hazards model to evaluate factors associated with the development of new-onset hypopituitarism. RESULTS: At last follow-up, 248 patients had developed new pituitary hormone deficiency (86 with NFPA, 66 with CD, and 96 with acromegaly). Among these patients, 150 (60.5%) had single and 98 (39.5%) had multiple hormone deficiencies. New hormonal changes included 82 cortisol (21.6%), 135 thyrotropin (35.6%), 92 gonadotropin (24.3%), 59 growth hormone (15.6%), and 11 vasopressin (2.9%) deficiencies. The actuarial 1-year, 3-year, 5-year, 7-year, and 10-year rates of hypopituitarism were 7.8%, 16.2%, 22.4%, 27.5%, and 31.3%, respectively. The median time to hypopituitarism onset was 39 months.In univariate analyses, an increased rate of new-onset hypopituitarism was significantly associated with a lower isodose line (p = 0.006, HR = 8.695), whole sellar targeting (p = 0.033, HR = 1.452), and treatment of a functional pituitary adenoma as compared with an NFPA (p = 0.008, HR = 1.510). In multivariate analyses, only a lower isodose line was found to be an independent predictor of new-onset hypopituitarism (p = 0.001, HR = 1.38). CONCLUSIONS: Hypopituitarism remains the most common unintended effect of GKRS for a pituitary adenoma. Treating the target volume at an isodose line of 50% or greater and avoiding whole-sellar radiosurgery, unless necessary, will likely mitigate the risk of post-GKRS hypopituitarism. Follow-up of these patients is required to detect and treat latent endocrinopathies.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Cordeiro D, Xu Z, Mehta GU, et al. Hypopituitarism after Gamma Knife radiosurgery for pituitary adenomas: a multicenter, international study. J Neurosurg. 2018. PMID: 31369225. doi:10.3171/2018.5.JNS18509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。